1. Compston, A, Coles, A. Multiple sclerosis. Lancet 2008; 372: 1502–1517. 2008/10/31.
Google Scholar | Crossref | Medline | ISI2. Baecher-Allan, C, Kaskow, BJ, Weiner, HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron 2018; 97: 742–768. 2018/02/23.
Google Scholar | Crossref | Medline3. Bjartmar, C, Kidd, G, Mork, S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893–901. 2000/12/16.
Google Scholar | Crossref | Medline | ISI4. Horakova, D, Dwyer, MG, Havrdova, E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci 2009; 282: 112–119. 2009/01/27. DOI: 10.1016/j.jns.2008.12.005.
Google Scholar | Crossref | Medline | ISI5. Houtchens, MK, Benedict, RH, Killiany, R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213–1223. 2007/09/19.
Google Scholar | Crossref | Medline | ISI6. Rocca, MA, Battaglini, M, Benedict, RH, et al. Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 2017; 88: 403–413. 2016/12/18.
Google Scholar | Crossref | Medline7. Kuhle, J, Disanto, G, Lorscheider, J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639–1643. 2015/03/27.
Google Scholar | Crossref | Medline | ISI8. Kuhle, J, Nourbakhsh, B, Grant, D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 2017; 88: 826–831. 2017/02/06.
Google Scholar | Crossref | Medline | ISI9. Varhaug, KN, Barro, C, Bjornevik, K, et al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2018; 5: e422. 2017/12/07.
Google Scholar | Crossref | Medline10. Disanto, G, Barro, C, Benkert, P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857–870. 2017/05/18.
Google Scholar | Crossref | Medline | ISI11. Novakova, L, Zetterberg, H, Sundstrom, P, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 2017; 89: 2230–2237. 2017/10/29.
Google Scholar | Crossref | Medline12. Kuhle, J, Barro, C, Disanto, G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016; 22: 1550–1559. 2016/01/13.
Google Scholar | SAGE Journals | ISI13. Barro, C, Benkert, P, Disanto, G, et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 2018: 2382-2391. 2018/06/04. DOI: 10.1093/brain/awy154.
Google Scholar | Crossref | Medline14. Hakansson, I, Tisell, A, Cassel, P, et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation 2018; 15: 209. 2018/07/20.
Google Scholar | Crossref | Medline15. Canto, E, Barro, C, Zhao, C, et al. Association between Serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol 2019: 1359-1366. 2019/08/14. DOI: 10.1001/jamaneurol.2019.2137.
Google Scholar | Crossref | Medline16. Chitnis, T, Gonzalez, C, Healy, BC, et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol 2018; 5: 1478–1491. 2018/12/20.
Google Scholar | Crossref | Medline17. Jakimovski, D, Kuhle, J, Ramanathan, M, et al. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 2019; 6: 1757–1770. 2019/08/23.
Google Scholar | Crossref | Medline18. Tortorella, C, Direnzo, V, Ruggieri, M, et al. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2018; 24: 1039–1045. 2017/05/26.
Google Scholar | SAGE Journals | ISI19. Rosso, M, Healy, BC, Saxena, S, et al. MRI Lesion state modulates the relationship between serum neurofilament light and age in multiple sclerosis. J Neuroimaging 2021: 388-393. 2021/01/22. DOI: 10.1111/jon.12826.
Google Scholar | Crossref20. Rosso, M, Gonzalez, CT, Healy, BC, et al. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol 2020; 7: 945–955. 2020/05/27.
Google Scholar | Crossref | Medline21. Gauthier, SA, Glanz, BI, Mandel, M, et al. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev 2006; 5: 532–536. Review 2006/10/10.10.1016/j.autrev.2006.02.012.
Google Scholar | Crossref | Medline | ISI22. Meier, DS, Guttmann, CRG, Tummala, S, et al. Dual-sensitivity multiple sclerosis lesion and CSF segmentation for multichannel 3 T brain MRI. J Neuroimaging 2018; 28: 36–47. 2017/12/14.
Google Scholar | Crossref | Medline23. Fadda, G, Brown, RA, Magliozzi, R, et al. A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis. Ann Neurol 2019; 85: 340–351. 2019/02/06.
Google Scholar | Crossref | Medline24. Mesaros, S, Rocca, MA, Absinta, M, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008; 70: 1107–1112. 2008/02/15.
Google Scholar | Crossref | Medline | ISI25. Magon, S, Tsagkas, C, Gaetano, L, et al. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis. J Neurol 2020: 1536-1546. 2020/02/11. DOI: 10.1007/s00415-020-09740-4.
Google Scholar | Crossref26. Schoonheim, MM, Hulst, HE, Brandt, RB, et al. Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 2015; 84: 776–783. 2015/01/27.
Google Scholar | Crossref | Medline27. Bisecco, A, Rocca, MA, Pagani, E, et al. Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: a multicenter study. Hum Brain Mapp 2015; 36: 2809–2825. 2015/04/16.
Google Scholar | Crossref | Medline | ISI28. Benedict, RH, Hulst, HE, Bergsland, N, et al. Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Mult Scler 2013; 19: 1478–1484. 2013/03/06.
Google Scholar | SAGE Journals | ISI29. Motl, RW, Zivadinov, R, Bergsland, N, et al. Thalamus volume and ambulation in multiple sclerosis: a cross-sectional study. Neurodegener Dis Manag 2016; 6: 23–29. 2016/01/20.
Google Scholar | Crossref | Medline30. Capone, F, Collorone, S, Cortese, R, et al. Fatigue in multiple sclerosis: the role of thalamus. Mult Scler 2020; 26: 6–16. 2019/05/30.
Google Scholar | SAGE Journals | ISI31. Wagenknecht, N, Becker, B, Scheld, M, et al. Thalamus degeneration and inflammation in two distinct multiple sclerosis animal models. J Mol Neurosci 2016; 60: 102–114. 2016/08/06.
Google Scholar | Crossref | Medline32. Dupuy, SL, Tauhid, S, Hurwitz, S, et al. The effect of dimethyl fumarate on cerebral gray matter atrophy in multiple sclerosis. Neurol Ther 2016; 5: 215–229. 2016/10/17.
Google Scholar | Crossref | Medline33. Henry, RG, Shieh, M, Amirbekian, B, et al. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009; 282: 61–66. 2009/04/28.
Google Scholar | Crossref | Medline | ISI34. Tsagkas, C, Chakravarty, MM, Gaetano, L, et al. Longitudinal patterns of cortical thinning in multiple sclerosis. Hum Brain Mapp 2020: 2198-2215. 2020/02/19. DOI: 10.1002/hbm.24940.
Google Scholar | Crossref | Medline35. Mike, A, Glanz, BI, Hildenbrand, P, et al. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3 T MR imaging. AJNR Am J Neuroradiol 2011; 32: 515–521. 2011/02/12.
Google Scholar | Crossref | Medline | ISI36. Calabrese, M, Reynolds, R, Magliozzi, R, et al. Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients. PLoS One 2015; 10: e0135428. 2015/08/13.
Google Scholar | Crossref | Medline | ISI37. Magliozzi, R, Howell, OW, Reeves, C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477–493. 2010/10/27.
Google Scholar | Crossref | Medline | ISI38. Zurawski, J, Tauhid, S, Chu, R, et al. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler 2020; 26: 177–187. 2019/11/13.
Google Scholar | SAGE Journals | ISI39. Bar-Or, A, Hintzen, RQ, Dale, RC, et al. Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology 2016; 87: S12–S19. 2016/08/31.
Google Scholar | Crossref | Medline40. Ceccarelli, A, Jackson, JS, Tauhid, S, et al. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. AJNR Am J Neuroradiol 2012; 33: 1579–1585. 2012/03/31.
Google Scholar | Crossref | Medline | ISI41. Gunnarsson, M, Malmestrom, C, Axelsson, M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–89. 2011/02/01.
Google Scholar | Crossref | Medline | ISI42. Axelsson, M, Malmestrom, C, Gunnarsson, M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20: 43–50. 2013/05/25.
Google Scholar | SAGE Journals | ISI43. Novakova, L, Axelsson, M, Khademi, M, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler 2017; 23: 62–71. 2016/03/24.
Google Scholar | SAGE Journals | ISI44. Sejbaek, T, Nielsen, HH, Penner, N, et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry 2019; 90: 1324–1330. 2019/10/16.
Google Scholar | Medline45. Kuhle, J, Kropshofer, H, Haering, DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019; 92: e1007–e1015. 2019/02/10.
Google Scholar | Crossref | Medline